Temming K - Search Results

1

Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels.

Temming K, Meyer DL, Zabinski R, Dijkers EC, Poelstra K, Molema G, Kok RJ. Temming K, et al. Bioconjug Chem. 2006 Nov-Dec;17(6):1385-94. doi: 10.1021/bc060087z. Bioconjug Chem. 2006. PMID: 17105215

2

RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature.

Temming K, Schiffelers RM, Molema G, Kok RJ. Temming K, et al. Drug Resist Updat. 2005 Dec;8(6):381-402. doi: 10.1016/j.drup.2005.10.002. Epub 2005 Nov 23. Drug Resist Updat. 2005. PMID: 16309948 Review.

3

Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology.

Temming K, Lacombe M, van der Hoeven P, Prakash J, Gonzalo T, Dijkers EC, Orfi L, Kéri G, Poelstra K, Molema G, Kok RJ. Temming K, et al. Bioconjug Chem. 2006 Sep-Oct;17(5):1246-55. doi: 10.1021/bc0600158. Bioconjug Chem. 2006. PMID: 16984135

4

Rational design of RGD-albumin conjugates for targeted delivery of the VEGF-R kinase inhibitor PTK787 to angiogenic endothelium.

Temming K, Lacombe M, Schaapveld RQ, Orfi L, Kéri G, Poelstra K, Molema G, Kok RJ. Temming K, et al. ChemMedChem. 2006 Nov;1(11):1200-3. doi: 10.1002/cmdc.200600201. ChemMedChem. 2006. PMID: 16991175 No abstract available.

5

Improved efficacy of alphavbeta3-targeted albumin conjugates by conjugation of a novel auristatin derivative.

Temming K, Meyer DL, Zabinski R, Senter PD, Poelstra K, Molema G, Kok RJ. Temming K, et al. Mol Pharm. 2007 Sep-Oct;4(5):686-94. doi: 10.1021/mp0700312. Epub 2007 Aug 8. Mol Pharm. 2007. PMID: 17683157

6

Organ- and cell-type specific delivery of kinase inhibitors: a novel approach in the development of targeted drugs.

Temming K, Fretz MM, Kok RJ. Temming K, et al. Curr Mol Pharmacol. 2008 Jan;1(1):1-12. Curr Mol Pharmacol. 2008. PMID: 20021419 Review.

7

Targeting of the VEGF-kinase inhibitor PTK787 to angiogenic vasculature using RGD-equipped albumin carrier molecules.

Temming K, Lacombe M, Moorlag HE, Asgeirsdottir SA, Orfi L, Kéri G, Poelstra K, Molema G, Kok RJ. Temming K, et al. J Control Release. 2006 Nov 28;116(2):e57. doi: 10.1016/j.jconrel.2006.09.048. J Control Release. 2006. PMID: 17718970 No abstract available.

8

Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology.

Gonzalo T, Talman EG, van de Ven A, Temming K, Greupink R, Beljaars L, Reker-Smit C, Meijer DK, Molema G, Poelstra K, Kok RJ. Gonzalo T, et al. Among authors: temming k. J Control Release. 2006 Mar 10;111(1-2):193-203. doi: 10.1016/j.jconrel.2005.12.010. Epub 2006 Feb 7. J Control Release. 2006. PMID: 16466667

9

Antivascular therapies: targets beyond the vessel wall.

Temming K, Kok RJ. Temming K, et al. ChemMedChem. 2007 Apr;2(4):433-5. doi: 10.1002/cmdc.200600304. ChemMedChem. 2007. PMID: 17315256 Review. No abstract available.

10

Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells.

Gonzalo T, Beljaars L, van de Bovenkamp M, Temming K, van Loenen AM, Reker-Smit C, Meijer DK, Lacombe M, Opdam F, Kéri G, Orfi L, Poelstra K, Kok RJ. Gonzalo T, et al. Among authors: temming k. J Pharmacol Exp Ther. 2007 Jun;321(3):856-65. doi: 10.1124/jpet.106.114496. Epub 2007 Mar 16. J Pharmacol Exp Ther. 2007. PMID: 17369283

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

184 results

Search Page

Filters